

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LEPU SCIEN TECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2291)

INSIDE INFORMATION POSITIVE PROFIT ALERT

This announcement is made by LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (the “**Company**”) and its subsidiaries (collectively, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the review of the Group’s preliminary unaudited consolidated management accounts for the six months ended June 30, 2023 (the “**Reporting Period**”), the Group is expected to record a net profit attributable to the Shareholders of approximately RMB73 million, representing an increase of around 200% as compared to the corresponding period last year. It is estimated that the non-IFRS profit is approximately RMB85 million. The expected increase in net profit attributable to the Shareholders was mainly due to the followings:

- (1) the sales volume of the Group’s last generation of nitinol occluder products in the Reporting Period increased significantly compared with the corresponding period last year. This growth was driven by the broad market acceptance of these products, enabled by the Group’s extensive distributor network, effective academic promotion, and strong marketing capabilities; and
- (2) the Group commenced sales of the MemoSorb® full-biodegradable polymer-based occluder systems following the commercialization of this product, which generated an additional revenue stream for the Group in the Reporting Period as compare with the corresponding period last year.

In the second half of 2023, the Company will further advance the upgrade of its metal occluder products and promote its biodegradable occluder products on a larger scale. The Company believes that the Group will not only maintain but also expand its robust business performance, aiming to deliver even better returns to the Shareholders in 2023.

As the Group's unaudited interim results for the Reporting Period has not yet been finalised, the information contained in this announcement is based on information that is currently available to the Board and the preliminary unaudited consolidated management accounts of the Group for the Reporting Period which have not yet been reviewed by the Company's audit committee. The unaudited interim results of the Group for the Reporting Period are expected to be published before the end of August 2023.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Ms. Chen Juan
Chairman of the Board and Executive Director

Shanghai, the People's Republic of China
July 7, 2023

As at the date of this announcement, the Board comprises Ms. Chen Juan and Ms. Zhang Yuxin as executive Directors, Mr. Fu Shan and Mr. Zheng Guorui as non-executive Directors, and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Liu Daozhi as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd."*